Progress in R&D and technology, regulatory and monetary incentives for advancing the development of rare diseases treatment, and ongoing industry focus are key drivers of growth in the number of approved and emerging orphan drugs. As the number of rare disease approvals climbs, the discussion around orphan drug value assessment, particularly for curative gene therapies, is rapidly evolving. A key concern for developers is how payers will control the growing cost of orphan cell and gene therapies, which often command high prices, and how payer policy will affect prescribing of these essential treatments. This study analyzes the health technology assessment (HTA) and pricing and reimbursement (P&R) policies that regulate market access for orphan drugs, specifically exploring the evolving dynamics affecting reimbursement and uptake of current and emerging orphan drugs for existing therapies in spinal muscular atrophy (SMA) and beta thalassemia. The secret of market access success for gene therapies launched in these indications will serve as insightful case studies for emerging curative gene therapies in other rare diseases.
- Focusing on SMA and beta thalassemia, what factors influenced HTA and P&R outcomes for current orphan agents?
- What impact do gene therapies and other orphan drugs have on payer budgets? What measures will payers implement to rein in costs?
- What pharmacoeconomic models will payers use to assess the value of orphan drugs and gene therapies? How will curative therapies be valued?
- What funding mechanisms are used for orphan drugs, and what measures are used for controlling and monitoring prescribing across the top five European markets?
- How will prescribing barriers for current orphan drugs evolve, what challenges will emerging orphan drugs likely face in the near future? What can manufacturers do to encourage optimal pricing and reimbursement terms, and to drive uptake?
European Access & Reimbursement provides integrated brand-level and country-specific analysis of primary market research conducted with payers and prescribers to examine reimbursement dynamics and evaluate the impact of payer policy on prescribing.
France, Germany, Italy, Spain, and United Kingdom
Survey of 250 medical oncologists across the top 5 European markets (50 per country)Interviews with 10 payers top 5 European markets (2 per country).
KEY DRUGS COVERED
Spinraza, Zolgensma, risdiplam, branaplam, Zynteglo, luspatercept
- Actionable recommendations to optimize market access
- Market access success and stumbles
- Market access roadblocks
- Pricing and reimbursement dynamics
- Impact of payer policy and coverage on prescribing
- Market access outlook for emerging therapies
- Rare Diseases and Orphan Drugs - Top Five European Markets
- Access & Reimbursement - Rare Diseases and Orphan Drugs - Top Five European Markets - 2019
Author(s): Yulia Privolnev, MA; Ian Love, PhD; Janie Cox, PhD
Yulia Privolnev is a manager on the Global Market Access Insights team at Decision Resources Group, primarily focusing on European market access. She is responsible for monitoring, analyzing, and reporting on global market access through the production of DRG’s Global Market Access Solution (GMAS) and Access & Reimbursement products. Yulia’s specific focus is on all aspects of market access in Western and Eastern Europe, as well as external reference pricing (ERP) and managed entry agreements (MEAs) on a global scale. Yulia holds a bachelor’s degree from the University of Toronto and a master’s degree from the London School of Economics.
Ian is an analyst on the Infectious, Niche, and Rare Diseases team at Decision Resources Group, specializing in niche and rare diseases. Ian conducts primary and secondary research to gauge the market landscapes of these diseases, thoroughly analyzing disease etiology, current treatments, unmet need, and emerging therapies expected to impact their respective markets. He received his doctorate in biomedical sciences from the University of Massachusetts Medical School and his in cell & molecular biology from the Worcester Polytechnic Institute. Prior to joining Decision Resources Group, Dr. Love was an Instructor in the Department of Internal Medicine at Virginia Commonwealth University.
Janie Cox, PhD , is a Senior Director of European Market Access at Decision Resources Group, with primary responsibility for the company’s European Access & Reimbursement portfolio, the industry’s only primary market research solution that includes insights from both physicians and payers in Europe to get a true sense of how both parties determine access to the relevant pharmaceutical markets. Previously, Dr Cox specialized in analysis of the NSCLC markets in Decision Resources’ oncology department, and, prior to joining the company, was a managing editor at Thomson Reuters, where her primary responsibility was providing information disclosed at major pharmaceutical conferences as content for Thomson Pharma. Dr. Cox holds a from the University of Bristol and a in immunology and microbiology from the University of Strathclyde, Glasgow. She has also worked as a postdoctoral scientist at the Institute for Animal Health.